Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Dermatology
  • Dermatology News
  • Cendakimab Shows...

Cendakimab Shows Efficacy and Safety in Treating Moderate to Severe Atopic Dermatitis: Results from Clinical Trial

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-08-02T20:30:37+05:30  |  Updated On 2 Aug 2024 8:31 PM IST
Cendakimab Shows Efficacy and Safety in Treating Moderate to Severe Atopic Dermatitis: Results from Clinical Trial
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

USA: In a phase 2 randomized clinical trial of 221 patients with moderate to severe atopic dermatitis (AD), treatment with cendakimab, an investigational anti-interleukin (IL)-13 monoclonal antibody, demonstrated efficacy after 16 weeks.

The findings, published in JAMA Dermatology, demonstrated improvements in pruritus, skin clearance, and the extent and severity of AD compared with placebo. Cendakimab was generally safe and well-tolerated.

Cendakimab selectively targets interleukin (IL)-13, a type 2 cytokine involved in the pathogenesis of atopic dermatitis (AD), by blocking its binding to IL13R-α1 and IL13R-α2 receptors. Proof-of-concept studies in AD endorse cendakimab as a potential treatment for type 2 inflammatory diseases. Considering this, Andrew Blauvelt, Oregon Medical Research Center, Portland, Oregon, and colleagues aimed to evaluate the safety and efficacy of cendakimab compared with placebo in patients with moderate to severe AD.

For this purpose, the researchers conducted a phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging clinical trial from 2021 to 2021. It enrolled adult patients with moderate to severe AD and inadequate response to topical medications at 69 sites in 5 countries (Japan [n = 17], US [n = 26], Czech Republic [n = 8], Poland [n = 9], and Canada [n = 9]).

Patients were randomized in a 1:1:1:1 ratio to receive subcutaneous cendakimab, 360 mg, every two weeks; 720 mg, every two weeks; 720 mg, once weekly; or placebo.

The study evaluated the mean percentage change in Eczema Area and Severity Index (EASI) scores from baseline to week 16. Hierarchical testing with adjustment for multiple comparisons was conducted for the following comparisons: 720 mg once weekly versus placebo, followed by 720 mg every two weeks vs placebo, and finally, 360 mg every two weeks vs placebo.

The study led to the following findings:

  • Two-hundred twenty-one patients were randomized, and 220 received the study drug (43% women; mean age, 37.7 years; 720 mg, once weekly [24%]; 720 mg, every two weeks [25%]; 360 mg, every two weeks [25%]; placebo [26%]).
  • The primary efficacy endpoint was met for cendakimab, 720 mg, once weekly versus placebo (–84.4 versus –62.7) but missed statistical significance for 720 mg, every two weeks (–76.0 versus –62.7).
  • The treatment effect for 360 mg every two weeks (−16.3 versus placebo) was comparable with 720 mg once weekly (−21.8); however, significance was not claimed because the hierarchical testing sequence was interrupted.
  • Of patients with treatment-emergent adverse events leading to discontinuation, 7.4% received 720 mg once weekly; 3.6% 720 mg every two weeks; 1.8% 360 mg every two weeks; and 3.6% placebo.

"In the randomized clinical trial, cendakimab proved effective, safe, and well-tolerated for patients with moderate to severe atopic dermatitis (AD). The primary endpoint, a significant reduction in Eczema Area and Severity Index (EASI) scores at week 16, was achieved with the 720 mg once-weekly dose. Across all doses, cendakimab showed continuous improvement in AD over the 16-week treatment period," the researchers concluded.

Reference:

Blauvelt A, Guttman-Yassky E, Lynde C, et al. Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. Published online July 17, 2024. doi:10.1001/jamadermatol.2024.2131


JAMA DermatologyCendakimabatopic dermatitis
Source : JAMA Dermatology
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Journal Club Today

    Universal Heart Health Advice Ignores Realities in Low-Income Countries: Study Finds

    Universal Heart Health Advice Ignores Realities in Low-Income Countries: Study Finds

    View All

    Health News Today

    Health Bulletin 24/May/2025

    Health Bulletin 24/May/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok